Blocking metabotropic glutamate receptor subtype 7 (mGlu7) via the venus flytrap domain (VFTD) inhibits amygdala plasticity, stress, and anxiety-related behavior

  • Christine E. Gee
  • , Daniel Peterlik
  • , Christoph Neuhäuser
  • , Rochdi Bouhelal
  • , Klemens Kaupmann
  • , Grit Laue
  • , Nicole Uschold-Schmidt
  • , Dominik Feuerbach
  • , Kaspar Zimmermann
  • , Silvio Ofner
  • , John F. Cryan
  • , Herman Van Der Putten
  • , Markus Fendt
  • , Ivo Vranesic
  • , Ralf Glatthar
  • , Peter J. Flor

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Behavioral genetics identified mGlu7 as a key regulator of brain emotion circuits. Results: An mGlu7-selective, Venus flytrap domain (VFTD)-directed antagonist inhibits fear, synaptic plasticity, stress, and anxiety in rodents. Conclusion: Pharmacological blockers of mGlu7 may represent promising future anxiolytics and antidepressants in man. Significance: The VFTD region of class C GPCRs provides a promising target for computer-assisted drug design.

Original languageEnglish
Pages (from-to)10975-10987
Number of pages13
JournalJournal of Biological Chemistry
Volume289
Issue number16
DOIs
Publication statusPublished - 18 Apr 2014

Fingerprint

Dive into the research topics of 'Blocking metabotropic glutamate receptor subtype 7 (mGlu7) via the venus flytrap domain (VFTD) inhibits amygdala plasticity, stress, and anxiety-related behavior'. Together they form a unique fingerprint.

Cite this